Neil Warma
Chief Executive Officer chez PROMIS NEUROSCIENCES, INC.
Fortune : - $ au 31/03/2024
Profil
Neil K.
Warma is the founder of Medexact, Inc. (founded in 2000) and BioHealth Care LLC (founded in 2018).
He held the title of President at Medexact, Inc. in 2003 and Chief Executive Officer at BioHealth Care LLC in 2018-2019.
Mr. Warma's current job(s) include being the President, Chief Executive Officer & Director at ProMIS Neurosciences, Inc. since 2021, the Executive Chairman at Ridgeline Therapeutics since 2019, the Director at Biotechnology Innovation Organization since 2014, the Director at BioHouston, Inc. since 2009, and the Director at TMG Biosciences LLC since 2018.
Mr. Warma's former job(s) include being the President, Chief Executive Officer & Director at Viron Therapeutics, Inc. from 2004-2007, the President, Chief Executive Officer, CFO & Director at Opexa Therapeutics, Inc. from 2008-2017, the Chief Executive Officer at Tvardi Therapeutics, Inc., the President & Co-Chief Executive Officer at Genexine, Inc., and an Independent Director at Genexine, Inc. He also worked as the Head-International Pharma Policy & Advocacy at Novartis Pharmaceuticals from 1992-2000 and as the General Manager at I-Mab Biopharma US Ltd.
from 2019-2022.
Mr. Warma's education includes an MBA from York University and an undergraduate degree from the University of Toronto.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 02/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Neil Warma
| Sociétés | Poste | Début |
|---|---|---|
| PROMIS NEUROSCIENCES, INC. | Chief Executive Officer | 30/12/2023 |
BioHouston, Inc.
 BioHouston, Inc. Miscellaneous Commercial ServicesCommercial Services BioHouston, Inc. engages in life science and biotechnology commercialization. The firm's mission is to create an environment that will stimulate technology transfer and research commercialization, thereby generating economic wealth for the Houston region and making it a global competitor in life science commercialization. The company is headquartered in Houston, TX. | Director/Board Member | 01/09/2009 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | 01/01/2014 |
| Ridgeline Therapeutics | Chairman | 01/01/2019 |
TMG Biosciences LLC
 TMG Biosciences LLC Miscellaneous Commercial ServicesCommercial Services TMG Biosciences LLC provides biosurveillance and biotechnology consulting services. It assists clients to execute biosurveillance and microbial detection/characterization programs and providing subject matter expertise on biotechnology instrumentation. The company is headquartered in Austin, TX. | Director/Board Member | 01/01/2018 |
Anciens postes connus de Neil Warma
| Sociétés | Poste | Fin |
|---|---|---|
| I-Mab Biopharma US Ltd. | Corporate Officer/Principal | 01/01/2022 |
| BioHealth Care LLC | Chief Executive Officer | 01/01/2019 |
Tvardi Therapeutics, Inc.
 Tvardi Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tvardi Therapeutics, Inc. develops and commercializes medicines for the treatment of diverse cancers, chronic inflammatory and fibrotic diseases. The company was founded by David J. Tweardy and Ronald A. DePinho in 2017 and is headquartered in Houston, TX. | Chief Executive Officer | 12/12/2018 |
Opexa Therapeutics, Inc.
 Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Chief Executive Officer | 19/09/2017 |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ | ░░░░░░░░░░ |
Formation de Neil Warma
| York University | Masters Business Admin |
| University of Toronto | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| GENEXINE, INC. | Health Technology |
| Entreprise privées | 11 |
|---|---|
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Viron Therapeutics, Inc.
 Viron Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Viron Therapeutics, Inc. discovers and develops novel therapeutics for inflammatory disorders. Its products include VT-111a, a recombinant protein that functions to reduce monocyte infiltration to sites of viral infection, as well as inhibits cardiovascular damage due to coronary stent placement. The firm also develops VT-310, a glycoprotein for the treatment of cancer, VT-384 that inhibit interferon gamma production, VT-346, a glycoprotein that protects against human TNF-mediated inflammatory signals and VT-214, a chemokine binding protein. The company was founded in 1997 and is headquartered in London, Canada. | Health Technology |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | Health Technology |
BioHouston, Inc.
BioHouston, Inc. Miscellaneous Commercial ServicesCommercial Services BioHouston, Inc. engages in life science and biotechnology commercialization. The firm's mission is to create an environment that will stimulate technology transfer and research commercialization, thereby generating economic wealth for the Houston region and making it a global competitor in life science commercialization. The company is headquartered in Houston, TX. | Commercial Services |
| Medexact, Inc. | |
Novartis Pharmaceuticals
 Novartis Pharmaceuticals Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Pharmaceuticals is a German company that manufactures pharmaceutical products. The private company is based in Basel, Germany. | Health Technology |
TMG Biosciences LLC
TMG Biosciences LLC Miscellaneous Commercial ServicesCommercial Services TMG Biosciences LLC provides biosurveillance and biotechnology consulting services. It assists clients to execute biosurveillance and microbial detection/characterization programs and providing subject matter expertise on biotechnology instrumentation. The company is headquartered in Austin, TX. | Commercial Services |
Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tvardi Therapeutics, Inc. develops and commercializes medicines for the treatment of diverse cancers, chronic inflammatory and fibrotic diseases. The company was founded by David J. Tweardy and Ronald A. DePinho in 2017 and is headquartered in Houston, TX. | Commercial Services |
| Ridgeline Therapeutics | |
| I-Mab Biopharma US Ltd. | |
| BioHealth Care LLC |
